Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery

Inclusion Criteria:

1. Aged 18-65 years, female or male

2. Newly diagnosed GBM (WHO grade 4) patients with maximal surgical resection

3. c-MET overexpression diagnosed by IHC

4. KPS ≥60

5. Adequate hematological, renal, and hepatic function. All patients should meet the following criteria:

6. absolute neutrophil count (ANC) ≥1.5 × 109/L and platelet count≥100 × 109/L

7. serum creatinine clearance ≥80 mL/min

8. total bilirubin level ≤ 1.5 × ULN (except patients with Gilbert syndrome)

9. aspartate aminotransferase (AST) ≤ 3.0 × ULN, alanine aminotransferase (ALT) ≤ 3.0 × ULN, and AST/ALT < 2.5 × ULN

10. The patient and his/her family members were informed and provided signed andinformed consent

Exclusion Criteria:

1. Any previous postoperative treatment except for concurrent chemoradiotherapy;

2. Individuals unable to undergo cranial MRI examination;

3. Active hemorrhage detected by cranial CT or MRI scan before enrollment;

4. Uncontrolled hypertension;

5. Decompensated heart failure, unstable angina pectoris, acute myocardial infarction,or persistent and clinically significant arrhythmias within 3 months beforeenrollment;

6. Anti-HIV (+), or both anti-HCV and HCV-RNA (+), or HBsAg positive with HBV-DNA >1000IU/ml;

7. Individuals requiring long-term continuous use of hematopoietic growth factors orplatelet transfusions;

8. Pregnant or lactating women;

9. Individuals who have received other clinical trial drugs within 30 days before thefirst dose of the study drug;

10. Individuals deemed unsuitable for participation in this clinical trial by theinvestigator.